Pfizer Inc
Close on Oct 30, 2026Market cap $173.95BP/E 40.2Yield 5.64%
Pfizer Accrued rebates by Quarter
Accrued rebates — Medicaid, Medicare & commercial contracting (Current liabilities) ($M) ($M)
Pfizer Accrued rebates: $9,293M in Q2 2026, up 6.9% from a year earlier. That is the highest of the 36 quarters on record here.
Where the Q2 2026 figure comes from
Source: Form 10-Q (filed 2026-08-04) ↗
Reported in Form 10-Q / 10-K Note 17 — Revenue Deductions & Rebate Accruals.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Accrued rebates — Medicaid, Medicare & commercial contracting (Current liabilities) ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 28, 2026 | 9,293 | +6.9% | Form 10-Q (filed 2026-08-04) ↗ |
| Q1 2026 | Mar 29, 2026 | 8,846 | +9.0% | Form 10-Q (filed 2026-05-05) ↗ |
| Q4 2025 | Dec 31, 2025 | 7,909 | +9.9% | Form 10-Q (filed 2026-08-04) ↗ |
| Q3 2025 | Sep 28, 2025 | 9,157 | +11.0% | Form 10-Q (filed 2025-11-04) ↗ |
| Q2 2025 | Jun 29, 2025 | 8,692 | +29.2% | Form 10-Q (filed 2025-08-05) ↗ |
| Q1 2025 | Mar 30, 2025 | 8,119 | +38.1% | Form 10-Q (filed 2025-05-05) ↗ |
| Q4 2024 | Dec 31, 2024 | 7,195 | +29.7% | Form 10-K (filed 2026-02-26) ↗ |
| Q3 2024 | Sep 29, 2024 | 8,252 | +62.3% | Form 10-Q (filed 2024-11-04) ↗ |
| Q2 2024 | Jun 30, 2024 | 6,726 | +38.2% | Form 10-Q (filed 2024-08-05) ↗ |
| Q1 2024 | Mar 31, 2024 | 5,880 | +24.0% | Form 10-Q (filed 2024-05-08) ↗ |
| Q4 2023 | Dec 31, 2023 | 5,546 | +23.8% | Form 10-K (filed 2025-02-27) ↗ |
| Q3 2023 | Oct 1, 2023 | 5,083 | +27.4% | Form 10-Q (filed 2023-11-08) ↗ |
| Q2 2023 | Jul 2, 2023 | 4,868 | +25.6% | Form 10-Q (filed 2023-08-09) ↗ |
| Q1 2023 | Apr 2, 2023 | 4,743 | +22.9% | Form 10-Q (filed 2023-05-10) ↗ |
| Q4 2022 | Dec 31, 2022 | 4,479 | +17.5% | Form 10-K (filed 2024-02-22) ↗ |
| Q3 2022 | Oct 2, 2022 | 3,991 | +15.0% | Form 10-Q (filed 2022-11-09) ↗ |
| Q2 2022 | Jul 3, 2022 | 3,875 | +17.4% | Form 10-Q (filed 2022-08-10) ↗ |
| Q1 2022 | Apr 3, 2022 | 3,858 | +20.1% | Form 10-Q (filed 2022-05-11) ↗ |
| Q4 2021 | Dec 31, 2021 | 3,811 | +26.3% | Form 10-K (filed 2023-02-23) ↗ |
| Q3 2021 | Oct 3, 2021 | 3,470 | +6.1% | Form 10-Q (filed 2021-11-12) ↗ |
| Q2 2021 | Jul 4, 2021 | 3,301 | +2.8% | Form 10-Q (filed 2021-08-12) ↗ |
| Q1 2021 | Apr 4, 2021 | 3,211 | -5.8% | Form 10-Q (filed 2021-05-13) ↗ |
| Q4 2020 | Dec 31, 2020 | 3,017 | +20.1% | Form 10-K (filed 2022-02-24) ↗ |
| Q3 2020 | Sep 27, 2020 | 3,270 | -0.2% | Form 10-Q (filed 2020-11-05) ↗ |
| Q2 2020 | Jun 28, 2020 | 3,210 | -1.4% | Form 10-Q (filed 2020-08-06) ↗ |
| Q1 2020 | Mar 29, 2020 | 3,408 | +1.9% | Form 10-Q (filed 2020-05-07) ↗ |
| Q4 2019 | Dec 31, 2019 | 2,512 | -21.7% | Form 10-K (filed 2021-02-25) ↗ |
| Q3 2019 | Sep 29, 2019 | 3,275 | +1.2% | Form 10-Q (filed 2019-11-07) ↗ |
| Q2 2019 | Jun 30, 2019 | 3,256 | +7.1% | Form 10-Q (filed 2019-08-08) ↗ |
| Q1 2019 | Mar 31, 2019 | 3,344 | +14.1% | Form 10-Q (filed 2019-05-09) ↗ |
| Q4 2018 | Dec 31, 2018 | 3,208 | +20.0% | Form 10-K (filed 2020-02-27) ↗ |
| Q3 2018 | Sep 30, 2018 | 3,235 | – | Form 10-Q (filed 2018-11-08) ↗ |
| Q2 2018 | Jul 1, 2018 | 3,039 | – | Form 10-Q (filed 2018-08-09) ↗ |
| Q1 2018 | Apr 1, 2018 | 2,932 | – | Form 10-Q (filed 2018-05-10) ↗ |
| Q4 2017 | Dec 31, 2017 | 2,674 | +18.3% | Form 10-K (filed 2019-02-28) ↗ |
| Q4 2016 | Dec 31, 2016 | 2,261 | – | Form 10-K (filed 2018-02-22) ↗ |
Cite this data
StockData. (2026). Pfizer Accrued rebates ($M), quarterly Q4 2016–Q2 2026 [Data set]. Compiled from Pfizer SEC filings and investor materials. https://stockdatahq.com/stocks/pfe/kpis/gtn-cur-rebates
See every metric in the Pfizer KPI table. Data updated Nov 2, 2026.